Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients - Cross, Anne H.; Stark, Jennifer L.; Lauber, Joanne; Ramsbottom, Michael J.; Lyons, Jeri-Anne (Journal of neuroimmunology, 2006)
Keywords: Adult; Antibodies, Monoclonal - immunology; Antibodies, Monoclonal - pharmacology; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Murine-Derived; Antibody Formation - drug effects; Antibody Formation - immunology; Antigens, CD20 - immunology; Autoantibodies; Autoantibodies - analysis; Autoantibodies - blood; Autoantibodies - immunology; B lymphocytes; B-Lymphocytes - drug effects; B-Lymphocytes - immunology; Cerebrospinal Fluid - cytology; Cerebrospinal Fluid - immunology; Down-Regulation - drug effects; Down-Regulation - immunology; Female; Flow Cytometry; Glatiramer Acetate; Humans; Immunity, Cellular - drug effects; Immunity, Cellular - immunology; Immunologic Factors - immunology; Immunologic Factors - pharmacology; Immunologic Factors - therapeutic use; Immunosuppression - methods; Interferon beta-1a; Interferon beta-1b; Interferon-beta - therapeutic use; Male; Middle Aged; Multiple sclerosis; Multiple Sclerosis, Relapsing-Remitting - cerebrospinal fluid; Multiple Sclerosis, Relapsing-Remitting - drug therapy; Multiple Sclerosis, Relapsing-Remitting - immunology; Myelin basic protein antibodies; Myelin oligodendrocyte glycoprotein antibodies; Myelin Proteins - immunology; Peptides - therapeutic use; Rituximab; T-Lymphocytes - drug effects; T-Lymphocytes - immunology; Treatment; Treatment Outcome; Multiple sclerosis; Myelin basic protein antibodies; Treatment; Autoantibodies; B lymphocytes; Rituximab; Myelin oligodendrocyte glycoprotein antibodies